Condition: Advanced Breast Cancer · Advanced Breast Carcinoma · Hormone Receptor Positive Breast Carcinoma · Sponsor: MedSIR
This trial studies a type of advanced breast cancer defined as hormone receptor HR-positive/HER2-negative and classified as non-luminal by gene expression profiling (PAM50). Patients will be treated with trastuzumab deruxtecan (T-DXd) or with physician's choice of CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET). The main purpose of the study is to analyze the efficacy of T-DXd in patients who have HR-positive and HER2-low/ultralow advanced breast cancer classified as non-luminal subtype.
This description comes directly from the study's public registry record.
MEDSIR · + 34 932 214 135 · contact.trials@medsir.org
Always discuss trial participation with your own doctor first.
| Kepler Universitäts Klinikum | Linz, Austria | Recruiting |
| Medical University of Vienna | Vienna, Austria | Recruiting |
| Algemeen Ziekenhuis Klina | Brasschaat, Belgium | Recruiting |
| Ghent University Hospital | Ghent, Belgium | Recruiting |
| CHU Helora - Hopital de Mons | Mons, Belgium | Recruiting |
| Cliniques universitaires Saint-Luc | Woluwe-Saint-Lambert, Belgium | Recruiting |
| Centre Francois Baclesse | Caen, France | Recruiting |
| CHU Lyon Sud | Lyon, France | Recruiting |
| Institute Paoli Calmettes | Marseille, France | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| CHU Saint Etienne | Saint-Priest-en-Jarez, France | Recruiting |
| MVZ Klinikum Aschaffenburg | Aschaffenburg, Germany | Recruiting |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06486883